ARCUTIS BIOTHERAPEUTICS, INC. Purchase Obligation, to be Paid, Year Four
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Purchase Obligation, to be Paid, Year Four of $600.00 thousand as of 2021-12-31, per its 10-K filed 2022-02-22.
Discontinued › Notes › Commitment and Contingencies
us-gaap:PurchaseObligationDueInFourthYear · last filed 2022-02-22
- 2021-12-31: Purchase Obligation, to be Paid, Year Four $600.00K.
- 2021-09-30: Purchase Obligation, to be Paid, Year Four $600.00K.
| Period end | Purchase Obligation, to be Paid, Year Four |
|---|---|
| 2021-12-31 | $600.00K 10-K · filed 2022-02-22 |
| 2021-09-30 | $600.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |